CorFlow Therapeutics

Executive Summary

CorFlow Therapeutics is a Swiss diagnostics company developing the CoFI System, a novel platform designed to identify and address coronary microvascular disease, particularly microvascular obstruction (MVO) in heart attack patients. The coronary microcirculation plays a critical role in regulating blood flow to the heart, and MVO is a key driver of poor outcomes after ST-elevation myocardial infarction (STEMI). Current diagnostic tools lack the ability to accurately assess microvascular function in real time, leaving a significant unmet need. CorFlow's proprietary system aims to provide interventional cardiologists with actionable insights during primary percutaneous coronary intervention (pPCI), potentially improving patient stratification and guiding therapy. The company, founded in 2015 and headquartered in Baar, Switzerland, has positioned itself at the intersection of diagnostics and interventional cardiology. While specific funding and pipeline details are limited, the CoFI System's focus on a high-impact clinical problem suggests meaningful potential in the precision medicine landscape.

Upcoming Catalysts (preview)

• Q2 2026Initiation or completion of pivotal clinical trial for CoFI System60% success
• Q4 2026CE marking or FDA breakthrough device designation50% success
• Q3 2026Strategic partnership with major cardiovascular device company35% success